Pageltra (Eltrombopag)

Eltrombopag acts on the thrombopoietin pathway to increase platelet counts in several hematologic conditions.

• Chronic immune thrombocytopenia (ITP): Improves platelet counts and reduces bleeding risk.
• Severe aplastic anemia: Supports hematopoiesis as an adjunct therapy.
• Hepatitis C‑related thrombocytopenia: Helps maintain platelet levels during antiviral treatment.

• Eltrombopag binds to the transmembrane domain of the thrombopoietin receptor (c‑Mpl) on megakaryocyte precursors, activating intracellular signaling pathways (JAK/STAT, MAPK). This mimics natural thrombopoietin, promoting proliferation and differentiation of megakaryocytes, which increases platelet production in the bone marrow.

Adverse reactions to eltrombopag are reported across a range of frequencies.

Common Side Effects

• Headache: Mild to moderate intensity.
• Nausea: Often transient and self‑limiting.
• Diarrhea: Usually mild and resolves without intervention.
• Fatigue: Generalized tiredness reported by some patients.
• Elevated liver enzymes: Mild increases in ALT/AST.
• Upper respiratory tract infection symptoms.

Serious or Rare Side Effects

• Hepatotoxicity: Significant elevation of liver enzymes or liver injury.
• Thromboembolic events: Deep vein thrombosis or pulmonary embolism.
• Bone marrow fibrosis: Rare progression of marrow scarring.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Acute myeloid leukemia transformation: Very rare but reported.
• Severe thrombocytosis: Excessively high platelet counts leading to clot risk.

When prescribing eltrombopag, clinicians should consider several safety measures.

• Liver function monitoring: Check ALT, AST, and bilirubin before and during therapy.
• Platelet count surveillance: Adjust dose based on platelet response to avoid thrombosis.
• Contraindication in patients with known hypersensitivity to eltrombopag or its excipients.
• Caution in patients with a history of thromboembolic disease or hepatic impairment.
• Pregnancy and lactation: Use only if the potential benefit justifies the risk.
• Store at ambient temperature: Keep below 25°C, retain original packaging, and protect from moisture.

Eltrombopag may interact with several medicines, affecting its absorption or safety profile.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: Reduce oral absorption of eltrombopag.
• Strong CYP1A2 inducers (e.g., rifampicin): Decrease plasma concentrations, reducing efficacy.
• Oral contraceptives: Potentially lower effectiveness of hormonal contraception.

Moderate Interactions (Monitor Closely)

• Warfarin: May increase INR; monitor coagulation parameters.
• Cyclosporine: Can raise eltrombopag levels, requiring dose adjustment.
• Fluoroquinolone antibiotics: May modestly affect platelet response.